Apimeds Pharmaceuticals US (APUS) Amortizatization of Intangibles (2024 - 2025)
Apimeds Pharmaceuticals US's (APUS) quarterly Amortizatization of Intangibles came in at $243177.0 in Q4 2025, up 288.35% on a YoY basis from $62618.0 in Q4 2024, and up 24317600.0% quarter-over-quarter from $1.0 in Q3 2025.
Powered by 
Analysis
Apimeds Pharmaceuticals US (APUS) Amortizatization of Intangibles (2024 - 2025) Analysis & Trends
Apimeds Pharmaceuticals US (APUS) has reported Amortizatization of Intangibles for 2 consecutive years, with $243177.0 the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Amortizatization of Intangibles rose 288.35% year-over-year to $243177.0; the trailing twelve-month figure through Dec 2025 stood at $283010.0 (up 140.41% YoY), and the FY2025 full-year result was $283010.0, up 140.41% from the prior year.
- Amortizatization of Intangibles climbed to $243177.0 in Q4 2025 per APUS's latest filing, from $1.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $243177.0 in Q4 2025 and bottomed at $1.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 600.00 Mn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | - |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | - |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 678,000.00 |
| 10 | Apimeds Pharmaceuticals US | 3.65 Mn | 3.65 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 243,177.00 |
| Sep 30, 2025 | 1.00 |
| Jun 30, 2025 | 13,056.00 |
| Mar 31, 2025 | 26,776.00 |
| Dec 31, 2024 | 62,618.00 |
| Sep 30, 2024 | 22,530.00 |
| Jun 30, 2024 | 13,619.00 |
| Mar 31, 2024 | 18,952.00 |